[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@VanMorrisMD](/creator/twitter/VanMorrisMD)
"Excellent talk from @EmerikOsterlund presenting research on ctDNA clearance patterns from pts w/ CRC in @MDAndersonNews INTERCEPT. Historical precedent for spontaneous ctDNA clearance using WES approach will help inform future trial design Accompanied by insightful perspective from the always incredible @aparna1024 . #endcancer"  
[X Link](https://x.com/VanMorrisMD/status/1979905891789885670) [@VanMorrisMD](/creator/x/VanMorrisMD) 2025-10-19T13:42Z 2511 followers, 2339 engagements


"🤯 🤯 Fantastic analysis of AtezoTRIBE and AVETRIC trials utilizing AI to predict benefit from IO in pts w/ MSS CRC- its wild that this biomarker work can be done from a single archival H&E slide. This approach will improve feasibility to analyze biomarkers in large multi-center trials moving forward. Industry should take note 👏 to @ChiaraCrem1 and study team"  
[X Link](https://x.com/VanMorrisMD/status/1980179738032497001) [@VanMorrisMD](/creator/x/VanMorrisMD) 2025-10-20T07:50Z 2511 followers, 3244 engagements


"Does chemotherapy affect the biology of BRAF V600E mCRC when combined with encorafenib + ceruximab Answer appears to be YES Very intriguing translational finding showing that addition of chemo to E+C reduces development of acquired RAS MAP2K1 and other mutations that drive resistance to BRAF + EGFR blockade. Will use this data in counseling patients why we add chemo to E+C in this pt population. 👏 to BREAKWATER team for releasing translational data on their large XXX pt () analysis And congrats to the always amazing @skopetz for an incredible presentation- our @MDAndersonNews team remains so"  
[X Link](https://x.com/VanMorrisMD/status/1980167996027867399) [@VanMorrisMD](/creator/x/VanMorrisMD) 2025-10-20T07:03Z 2511 followers, 9176 engagements


"Interesting ph3 trial showing XXX month OS benefit with zanzalintinib+ atezolizumab vs rego in pts w/ treatment-ref MSS CRC- toxicity significant and excited to see more mature data in the future. Congrats to @AnwaarSaeed3 for leading this ph X trial"  
[X Link](https://x.com/VanMorrisMD/status/1980181159926521942) [@VanMorrisMD](/creator/x/VanMorrisMD) 2025-10-20T07:55Z 2511 followers, 5208 engagements